| Report ID | 269871 |
| Drug Identification Number | 02474433 |
| Brand name | OGIVRI |
| Common or Proper name | TRASTUZUMAB |
| Company Name | BIOSIMILAR COLLABORATIONS IRELAND LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | WATER TRASTUZUMAB |
| Strength(s) | 20ML 440MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 1VL TRASTUZUMAB 1VL BWFI |
| ATC code | L01FD |
| ATC description | |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2025-10-10 |
| Estimated end date | 2025-11-21 |
| Actual end date | 2025-11-25 |
| Shortage status | Resolved |
| Updated date | 2025-11-26 |
| Company comments | Delay due to disruption in drug product release. Ogivri 150 mg/vial (DIN 02474425) is available. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | GRANGE PARADE, BALDOYLE INDUSTRIAL ESTATE, DUBLIN 13 DUBLIN, -- IRELAND D13R20R |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-10-18 | English | Compare |
| v1 | 2025-10-18 | English | Compare |